撒哈拉以南非洲的癌症基因突变流行率:现有数据回顾

IF 3 3区 医学 Q2 ONCOLOGY
Joshua Shain, Alissa Michel, Michael S. May, Lindor Qunaj, Wafaa El-Sadr, Wendy K. Chung, Paul S. Appelbaum, Judith S. Jacobson, Jessica Justman, Alfred I. Neugut
{"title":"撒哈拉以南非洲的癌症基因突变流行率:现有数据回顾","authors":"Joshua Shain, Alissa Michel, Michael S. May, Lindor Qunaj, Wafaa El-Sadr, Wendy K. Chung, Paul S. Appelbaum, Judith S. Jacobson, Jessica Justman, Alfred I. Neugut","doi":"10.1053/j.seminoncol.2023.12.001","DOIUrl":null,"url":null,"abstract":"<h3>Background</h3><p>Cancer represents a leading cause of death worldwide. Germline mutations in several genes increase the risk of developing several cancers, including cancers of the breast, ovary, pancreas, colorectum, and melanoma. An understanding of the population prevalence of pathogenic germline mutations can be helpful in the design of public health interventions, such as genetic testing, which has downstream implications for cancer screening, prevention, and treatment. While population-based studies of pathogenic germline mutations exist, most such studies have been conducted in White populations. Limited data exist regarding the prevalence of germline mutations within sub-Saharan African populations.</p><h3>Materials and Methods</h3><p>We identified countries defined as sub-Saharan Africa by the World Bank and conducted a scoping literature review using PubMed. For each country, we identified and summarized studies that focused on the prevalence of germline genetic mutations with sample sizes &gt;10 and in a population directly from sub-Saharan Africa, either with or without diseases associated with the relevant genetic mutations. Studies that evaluated the prevalence of somatic or likely benign variants were excluded.</p><h3>Results</h3><p>Within the 48 countries in sub-Saharan Africa, we identified 34 studies which meet the inclusion criteria. Twenty studies were conducted in South Africa, Nigeria, or Burkina Faso; four countries had more than two published papers. We found that 33 of 48 countries in sub-Saharan Africa lacked any genetic studies. Notably, there has been an increase in relevant studies starting in 2020. Importantly, of the 34 studies identified, 29 included data on <em>BRCA</em>1 or <em>BRCA</em>2. Data on the prevalence of mutations contributing to familial cancer syndromes other than <em>BRCA</em>1 and <em>BRCA</em>2 was limited.</p><h3>Conclusions</h3><p>While some progress has been made towards understanding the prevalence of germline mutations in cancer susceptibility genes, the characterization of genetic mutations among sub-Saharan African populations remains strikingly incomplete. Given the genetic diversity in the region, there remains a great need for large-scale, population-based studies to understand the prevalence of germline pathogenic mutations and adequately capture all the subpopulations in this part of the world.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"72 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data\",\"authors\":\"Joshua Shain, Alissa Michel, Michael S. May, Lindor Qunaj, Wafaa El-Sadr, Wendy K. Chung, Paul S. Appelbaum, Judith S. Jacobson, Jessica Justman, Alfred I. Neugut\",\"doi\":\"10.1053/j.seminoncol.2023.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3>Background</h3><p>Cancer represents a leading cause of death worldwide. Germline mutations in several genes increase the risk of developing several cancers, including cancers of the breast, ovary, pancreas, colorectum, and melanoma. An understanding of the population prevalence of pathogenic germline mutations can be helpful in the design of public health interventions, such as genetic testing, which has downstream implications for cancer screening, prevention, and treatment. While population-based studies of pathogenic germline mutations exist, most such studies have been conducted in White populations. Limited data exist regarding the prevalence of germline mutations within sub-Saharan African populations.</p><h3>Materials and Methods</h3><p>We identified countries defined as sub-Saharan Africa by the World Bank and conducted a scoping literature review using PubMed. For each country, we identified and summarized studies that focused on the prevalence of germline genetic mutations with sample sizes &gt;10 and in a population directly from sub-Saharan Africa, either with or without diseases associated with the relevant genetic mutations. Studies that evaluated the prevalence of somatic or likely benign variants were excluded.</p><h3>Results</h3><p>Within the 48 countries in sub-Saharan Africa, we identified 34 studies which meet the inclusion criteria. Twenty studies were conducted in South Africa, Nigeria, or Burkina Faso; four countries had more than two published papers. We found that 33 of 48 countries in sub-Saharan Africa lacked any genetic studies. Notably, there has been an increase in relevant studies starting in 2020. Importantly, of the 34 studies identified, 29 included data on <em>BRCA</em>1 or <em>BRCA</em>2. Data on the prevalence of mutations contributing to familial cancer syndromes other than <em>BRCA</em>1 and <em>BRCA</em>2 was limited.</p><h3>Conclusions</h3><p>While some progress has been made towards understanding the prevalence of germline mutations in cancer susceptibility genes, the characterization of genetic mutations among sub-Saharan African populations remains strikingly incomplete. Given the genetic diversity in the region, there remains a great need for large-scale, population-based studies to understand the prevalence of germline pathogenic mutations and adequately capture all the subpopulations in this part of the world.</p>\",\"PeriodicalId\":21750,\"journal\":{\"name\":\"Seminars in oncology\",\"volume\":\"72 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1053/j.seminoncol.2023.12.001\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1053/j.seminoncol.2023.12.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景癌症是导致全球死亡的主要原因之一。几种基因的种系突变会增加罹患几种癌症的风险,包括乳腺癌、卵巢癌、胰腺癌、结直肠癌和黑色素瘤。了解致病性种系突变在人群中的流行程度有助于设计公共卫生干预措施,如基因检测,这对癌症筛查、预防和治疗具有下游影响。虽然存在基于人群的致病性种系突变研究,但大多数此类研究都是在白人人群中进行的。有关撒哈拉以南非洲人群种系突变患病率的数据有限。材料与方法我们确定了世界银行定义为撒哈拉以南非洲的国家,并使用 PubMed 进行了范围性文献综述。对于每个国家,我们都确定并总结了重点关注种系基因突变患病率的研究,这些研究的样本大小为 10,研究对象直接来自撒哈拉以南非洲地区的人群,无论是否患有与相关基因突变有关的疾病。结果在撒哈拉以南非洲的 48 个国家中,我们发现了 34 项符合纳入标准的研究。其中有 20 项研究是在南非、尼日利亚或布基纳法索进行的;有 4 个国家发表了两篇以上的论文。我们发现,在撒哈拉以南非洲的 48 个国家中,有 33 个国家缺乏任何基因研究。值得注意的是,从 2020 年开始,相关研究有所增加。重要的是,在已发现的 34 项研究中,29 项包含了 BRCA1 或 BRCA2 的数据。结论虽然在了解癌症易感基因种系突变的发生率方面取得了一些进展,但撒哈拉以南非洲人群的基因突变特征描述仍然非常不完整。鉴于该地区的遗传多样性,仍然非常有必要开展大规模、基于人群的研究,以了解种系致病基因突变的流行情况,并充分掌握世界上这一地区的所有亚人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data

Background

Cancer represents a leading cause of death worldwide. Germline mutations in several genes increase the risk of developing several cancers, including cancers of the breast, ovary, pancreas, colorectum, and melanoma. An understanding of the population prevalence of pathogenic germline mutations can be helpful in the design of public health interventions, such as genetic testing, which has downstream implications for cancer screening, prevention, and treatment. While population-based studies of pathogenic germline mutations exist, most such studies have been conducted in White populations. Limited data exist regarding the prevalence of germline mutations within sub-Saharan African populations.

Materials and Methods

We identified countries defined as sub-Saharan Africa by the World Bank and conducted a scoping literature review using PubMed. For each country, we identified and summarized studies that focused on the prevalence of germline genetic mutations with sample sizes >10 and in a population directly from sub-Saharan Africa, either with or without diseases associated with the relevant genetic mutations. Studies that evaluated the prevalence of somatic or likely benign variants were excluded.

Results

Within the 48 countries in sub-Saharan Africa, we identified 34 studies which meet the inclusion criteria. Twenty studies were conducted in South Africa, Nigeria, or Burkina Faso; four countries had more than two published papers. We found that 33 of 48 countries in sub-Saharan Africa lacked any genetic studies. Notably, there has been an increase in relevant studies starting in 2020. Importantly, of the 34 studies identified, 29 included data on BRCA1 or BRCA2. Data on the prevalence of mutations contributing to familial cancer syndromes other than BRCA1 and BRCA2 was limited.

Conclusions

While some progress has been made towards understanding the prevalence of germline mutations in cancer susceptibility genes, the characterization of genetic mutations among sub-Saharan African populations remains strikingly incomplete. Given the genetic diversity in the region, there remains a great need for large-scale, population-based studies to understand the prevalence of germline pathogenic mutations and adequately capture all the subpopulations in this part of the world.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Seminars in oncology
Seminars in oncology 医学-肿瘤学
CiteScore
6.60
自引率
0.00%
发文量
58
审稿时长
104 days
期刊介绍: Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信